Opinion|Videos|February 14, 2025
Eleanor’s Journey With KRAS+ Metastatic NSCLC
A 58-year-old retired teacher treated with adagrasib for KRAS+ metastatic NSCLC.
Advertisement
Episodes in this series
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.
Advertisement
Related to this article
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Advertisement
Advertisement
Trending on CancerNetwork
1
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
2
Contextualizing MRD Negativity and PFS Across Treatment Regimens in Relapsed/Refractory Multiple Myeloma
3
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
4
What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance
5